Introduction
The incidence and severity of communityacquired and nosocomial bacterial infections in children have been greatly reduced by the use of chemoprophylaxis and the early initiation of antibiotic therapy. As it is usually not feasible to perform diagnostic microbiology before starting treatment, in
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Beta-lactam antibiotics, especially the penicillins, played an important role in the management of pediatric infections for many years as they fulfilled most of the criteria required of an ideal empiric agent: they had a broad spectrum of activity against all likely pathogens, good bactericidal activity, and were easy to administer. Beta-lactam antibiotics are also free from interactions with other drugs, have a stable and predictable pharmacokinetic profile, and are well tolerated and safe at optimal therapeutic doses. 2 For the widest use, an antibiotic should also be resistant to breakdown by bacterial enzymes.
Unfortunately, the empiric use of betalactam antibiotics has been restricted in recent years by the increasing prevalence of beta-lactamase production by both community-acquired and nosocomial pathogens. It is now clear from widespread reports that beta-lactam resistance, mainly due to beta-lactamase production, presents a serious therapeutic problem worldwide. 2, 3 
Beta-lactam resistance
Resistance to beta-lactam antibiotics in Staphylococcus aureus was first described soon after the introduction of penicillin in the 1940s. 4 -6 Even before the commercial production of penicillin, persistent cultures can be detected in the first photographs published by Fleming in 1929. 7 The most common and efficient mechanism of resistance to beta-lactam antibiotics is the production of beta-lactamases, which catalyze the hydrolysis of the beta-lactam ring, resulting in a compound that can no longer inhibit bacterial cell-wall synthesis. Multicenter surveillance studies of pathogenic bacteria have reported a recent increase in the incidence of resistance to all beta-lactams, including carbapenems and cephalosporins, and resistance has now been described in many pathogens once considered to be beta-lactamase-negative.
The Gram-negative organism Moraxella catarrhalis (formerly Branhamella/Neisseria catarrhalis), which is a frequent cause of pediatric infections such as otitis media, is a good example of a pathogen that has acquired a high level of resistance to betalactam antibiotics. At the beginning of the antibiotic era, beta-lactamase production by this organism was not reported. The almost exclusive use of beta-lactams for many respiratory infections, however, has been accompanied by an increase in the number of isolates that are beta-lactam resistant, and today 80 -100% of all M. catarrhalis isolates worldwide produce beta-lactamases. 3, 8, 9 A similar increase in the incidence of betalactam resistance has also been reported among clinically significant Gram-positive and Gram-negative respiratory pathogens, common pathogens of the urinary tract, and anaerobic bacteria involved in a number of infections (Table 1) . 2,8 -12 Resistance to betalactams varies widely between different geographic regions, but for some pathogens, especially Klebsiella species and Pseudomonas aeruginosa, virtually all strains worldwide are beta-lactamase producers. 2
Overcoming the problem of beta-lactam resistance
Two approaches have been used to combat beta-lactamase-mediated resistance to betalactams: (i) Modification of the structure of the betalactam so that it still possesses bactericidal activity but is no longer susceptible to beta-lactamases; (ii) Inhibition of the beta-lactamase using a compound that is structurally related to the antibiotic, thus preventing the breakdown of the antibiotic.
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The first approach has met with only moderate success. The modified penicillins, including methicillin, oxacillin, nafcillin and cloxacillin, proved to have reduced spectra of antibacterial (anti-staphylococcal) activity, and their introduction has been met with the rapid evolution of bacterial pathogens with beta-lactamase-mediated resistance. 2, 13 Likewise, although the development of cephalosporins and carbapenems yielded compounds with broader antimicrobial spectra, resistance to these agents has been quick to develop. 14, 15 The development of beta-lactamase inhibitors was first attempted about 30 years ago. 16 -18 These inhibitors are structurally related to penicillin but have a modified sidechain that enables them to act as suicide inhibitors, binding irreversibly to the betalactamase and rendering it inactive. Thus, the breakdown of the antibiotic by the betalactamase is prevented and bactericidal activity is maintained. Currently, three betalactamase inhibitors (sulbactam, tazobactam, and clavulanic acid) are in clinical use, and five beta-lactam/beta-lactamase inhibitor combinations are available commercially ( Table 2 ). Some of these combinations are only formulated for parenteral use, whereas others such as ampicillin/sulbactam are also 13A available for oral administration and can therefore be used for the management of pediatric infections in the community.
In patients with infections caused by methicillin-resistant S. aureus and penicillinresistant Streptococcus pneumoniae, where the mechanisms of beta-lactam resistance do not involve beta-lactamase production, treatment with beta-lactam/beta-lactamase inhibitors will be of little value. In these patients, use of other classes of antibacterial agents, such as vancomycin, is recommended. 19
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IN VITRO SPECTRUM OF ACTIVITY
Beta-lactam/beta-lactamase inhibitors, such as ampicillin/sulbactam, have been shown to have in vitro activity against a wide range of Gram-positive and Gram-negative bacterial pathogens, including those known to produce beta-lactamases. 18, 20 Although susceptibility testing in vitro demonstrated no activity for penicillin, ampicillin, piperacillin or methicillin alone against a large number of beta-lactamase-producing bacterial pathogens, including Staphylococcus epidermidis, Streptococcus pyogenes, Enterococcus faecalis, Haemophilus influenzae, Neisseria gonorrhoeae, M. catarrhalis, Escherichia coli, and Klebsiella, Proteus, Enterobacter, Serratia, Acinetobacter, Bacteroides, Propionibacterium, and Clostridium species, most pathogens are inhibited using one of the beta-lactam/beta-lactamase inhibitor combinations. 18, 20 In addition to treating infections caused by betalactamase-producing pathogens, betalactam/beta-lactamase inhibitors may also be useful for the treatment of infections caused by beta-lactam-susceptible organisms where other non-pathogenic bacteria at the site of infection produce beta-lactamases that may lead to treatment failure. 21 Most beta-lactamase inhibitors have no significant intrinsic antibacterial activity and act as suicide inhibitors by competing with the beta-lactam antibiotic for the active site on the beta-lactamase. This results in an irreversible interaction between the enzyme and inhibitor, leading to inhibition and restoration of the bactericidal activity of the antibiotic. Sulbactam is the exception and has been shown to limit activity against Neisseria meningitidis and N. gonorrhoeae.
To date, no clinical resistance to these combination compounds has been reported and attempts to induce resistance in vitro have failed. Sulbactam does not appear to induce beta-lactamase production at all, whereas clavulanic acid is the only inhibitor that has been shown to induce betalactamase in Morganella morganii and is a potent inducer of beta-lactamase in Enterobacter cloacae. 22, 23 Furthermore, in vitro susceptibility studies revealed no increase in minimum inhibitory concentration (MIC) for ampicillin/sulbactam in ampicillin-resistant organisms repeatedly exposed to sublethal concentrations of this combination. 24, 25 This suggests that emergence of resistance is unlikely to limit the widespread clinical use of ampicillin/sulbactam.
PHARMACOKINETICS
If the combined beta-lactam/beta-lactamase inhibitor is to be effective clinically, high antibacterial concentrations of both drugs must be able to penetrate to the site of infection. Ampicillin and sulbactam have similar time-topeak plasma concentrations (approximately 1 h) and are excreted primarily in the urine (> 75%). 26 High body tissue and body fluid concentrations are achieved after parenteral administration (Table 3) , although the concentrations of ampicillin and sulbactam differ in various body tissues. Antibacterial
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concentrations of both drugs have been detected in pus, sputum, and middle-ear fluid. 26 Furthermore, enrichment of sulbactam (after a dose of 0.5 g or 1 g) has been reported in blister fluid, intraperitoneal fluid, and the intestinal mucosa compared with ampicillin when equivalent doses are administered (Table  3) . 27 Penetration of ampicillin/sulbactam into cerebrospinal fluid has been shown to occur primarily in the presence of inflamed meninges, with higher concentrations detected in patients with more severe meningeal inflammation. 26 Sulbactam is not well absorbed after oral administration, but this problem has been overcome by the chemical bonding of sulbactam to ampicillin via a double ester linkage, 28 resulting in the mutual prodrug sultamicillin. This prodrug is readily absorbed after oral administration and has antibiotic activity and clinical efficacies that are similar to those of the parenteral formulation. Sultamicillin is hydrolyzed by enzymes in the intestinal wall, releasing high serum and urine ampicillin and sulbactam concentrations. 21 Elevated serum levels and a wide tissue distribution of ampicillin and sulbactam are achieved after oral administration of sultamicillin. Peak plasma concentrations of ampicillin administered as sultamicillin are reported to be approximately twice those achieved with an equivalent dose of ampicillin alone. 19, 21 In contrast, the betalactam amoxicillin combined with clavulanic acid provides, dose-for-dose, approximately the same serum concentration of amoxicillin as when this antibiotic is administered alone. 21 Although sulbactam is two-to fivefold less potent than clavulanic acid as a betalactamase inhibitor, equivalent inhibition of beta-lactamases can be achieved at the doses of sulbactam used clinically. The elimination of ampicillin and sulbactam may be impaired in patients with renal failure, leading to increased serum levels and an increased half-life of both drugs. The optimum dosage of ampicillin and sulbactam should be determined carefully according to creatinine clearance in these patients.
CLINICAL EFFICACY
Beta-lactam/beta-lactamase inhibitors have been shown to be an effective treatment option for a wide variety of bacterial infections in infants, children, and adults. The therapeutic efficacy of parenteral and 
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oral formulations of ampicillin/sulbactam has been demonstrated in a number of clinical trials conducted in children with a wide variety of infections in which betalactamase-producing organisms, such as H. influenzae and M. catarrhalis, play a significant etiologic role. Excellent clinical response and bacteriologic eradication rates with ampicillin/sulbactam have been reported in upper and lower respiratory tract infections, skin and soft-tissue infections, intra-abdominal infections, urinary tract infections, osteomyelitis, and meningitis (Table 4) . 20,21,29 -34 Sultamicillin has been shown to be particularly effective in the treatment of community-acquired upper respiratory tract infections, which are common in children, and to provide comparable efficacy to oral amoxicillin, with or without clavulanic acid, in pediatric acute otitis media, 19, 32 and in uncomplicated urinary tract infections in adults. 35 Escherichia coli is the most frequently isolated pathogen in pediatric urinary tract infections, followed by Klebsiella, Staphylococcus, Pseudomonas, and Proteus species. In a recent study in Argentina, over 60% of E. coli isolates were found to be resistant to ampicillin and over 40% were resistant to co-trimoxazole (trimethoprim/sulfamethoxazole), the drug most commonly used worldwide in the management of uncomplicated urinary tract infection. In contrast, only 10% of isolates were resistant to ampicillin/sulbactam. 34 The high successful clinical response and bacteriologic eradication response rates with ampicillin/ sulbactam (85 -100%) seen in pediatric patients with various mild-to-moderate infections ( Table 4 ) are consistent with these in vitro findings.
Effective antimicrobial therapy remains a problem in neonates, and current treatment usually consists of empiric combinations of parenteral antibiotics. 31 Treatment is complicated by the fact that neonates have more extracellular fluid than adults (40% compared with 20% of body mass), which means that comparatively higher doses of antibiotics usually have to be administered. Of the beta-lactam/beta-lactamase combinations currently available, only ampicillin/ sulbactam has received widespread approval for use in neonatal infections; piperacillin/ tazobactam is not licensed for use in neonates in some countries.
In a study of 27 seriously ill neonates with urinary tract, skin and soft-tissue, or lower or 
upper respiratory tract infections (mainly pneumonia), Airede et al. 31 demonstrated clinical cure and bacteriologic eradication rates of 96.3% and 93.8%, respectively, following administration of sultamicillin 50 mg/kg per day. The bacteria responsible for these infections were mainly S. aureus, E. coli and K. pneumoniae, with a betalactamase production rate of 88%. Thus, sultamicillin also appears to be effective therapy for treating infections in neonates caused by Gram-positive and/or Gramnegative pathogens. Furthermore, ampicillin/ sulbactam can be combined with aminoglycosides in neonates without any associated problems.
As oral therapy may be difficult to give in the immediate newborn period and may not be well absorbed, parenteral administration of ampicillin/sulbactam is recommended in very sick neonates. A wide range of dosages (50 -400 mg/kg per day) has been used in the newborn, depending on the severity of the infection, the age of the baby, and the extent of prematurity.
SAFETY AND TOLERABILITY
The safety and tolerability of ampicillin/ sulbactam have been evaluated in 39 therapeutic studies and six prophylaxis studies involving both adult and pediatric patients. 36 Both safety and tolerability have been shown to be excellent, with mild adverse events being reported by less than 10% of patients in most studies, 18 although slight variations have been recorded in different countries. The incidence and type of sideeffect vary according to the route of administration of this combination. Mild diarrhea/loose stools and gastrointestinal disturbances are the most frequent side-effects reported with oral sultamicillin; this is thought to be due to the antibacterial effect of the drug on the normal intestinal flora. 19, 21 These side-effects are reported more frequently by patients taking tablets than those receiving sultamicillin oral suspension, but events are extremely rare in patients treated with parenteral ampicillin/sulbactam. 37 Injectionsite pain, which can be minimized by diluting the dose with lidocaine, is reported exclusively after intramuscular administration of ampicillin/sulbactam. 27, 36 In some patients, a maculopapular rash may be observed after ampicillin/sulbactam therapy. This is usually an allergic reaction, but in a seriously ill child the possibility of a concurrent viral infection, such as infectious mononucleosis, should not be ruled out.
In most studies, adverse events rarely lead to discontinuation of treatment and resolve either during therapy or shortly after the end of therapy. It is interesting to note that Pitts et al. 21 reported a reduction in the incidence of diarrhea in patients given parenteral ampicillin/sulbactam before being switched to oral therapy. Further studies are required to verify this observation.
ADMINISTRATION OF BETA-LACTAM/BETA-LACTAMASE INHIBITORS AND PATIENT COMPLIANCE
Beta-lactam/beta-lactamase inhibitors are currently formulated for both parenteral and oral administration ( Table 2) . Cefoperazone/ sulbactam, piperacillin/tazobactam, and ticarcillin/clavulanic acid are available for parenteral use, whereas both parenteral and oral formulations of ampicillin/sulbactam and amoxicillin/clavulanic acid are available.
The availability of intramuscular and intravenous formulations of ampicillin/ sulbactam, as well as oral formulations of sultamicillin, has two advantages: the efficacy and tolerability of this parenteral drug combination can be established before the patient is discharged from hospital, and sequential therapy can be given. Patients can be switched to the oral formulation as they improve clinically and are able to leave the hospital, thus establishing a smooth transition from hospital to community management.
Patient compliance is an important factor that determines therapeutic outcome: improved antibiotic compliance results in faster resolution of infection and a lower incidence of recurrence, and it has been suggested that it may also reduce the development of bacterial resistance. 38 Pediatric patients, especially those treated with antibiotics in the community, are associated with particularly poor compliance, 39, 40 but this can be improved by decreasing the frequency and duration of treatment. 41 In a review of 100 studies, significantly lower non-compliance levels were noted for once-daily or twice-daily regimens compared with three-or fourtimes-daily regimens, with no obvious advantage of once-daily over twice-daily dosing. 42 Ampicillin/sulbactam is usually administered to pediatric patients twice daily. As the daily dosage is divided into two rather than three doses, each individual dose is much higher, thus serum and tissue levels of ampicillin and sulbactam are higher after twice-daily than after three-times-daily dosing, with a correspondingly higher clinical success rate. Sultamicillin has the advantage that it can be administered orally as either tablets or an oral suspension. The oral suspension is given to children at a dosage of 50 mg/kg per day in two divided doses 12 h apart. This simple dosing regimen, which has stable pharmacokinetics, is associated with good patient compliance as it reduces the distress associated with taking medication on a more frequent basis.
Furthermore, the recommended course of ampicillin/sulbactam is significantly shorter than that of conventional antibiotics, which again increases patient compliance. It has been suggested that the problem of noncompliance in children with infections, such as tonsillitis, can be overcome by giving a single injection of long-acting penicillin.
However, it is doubtful whether this method of administering an antibiotic will be acceptable worldwide as children, and consequently mothers, find the experience distressing.
Conclusions
Ampicillin/sulbactam is an ideal empiric therapy for infections in pediatric patients as it has a broad spectrum of activity, is safe and well tolerated at therapeutic doses, and is available in a variety of formulations that are suitable for sequential therapy, thus ensuring a smooth transition from hospital to community management. Moreover, the simple treatment regimens and short course of therapy recommended with ampicillin/ sulbactam suggest that patient compliance with this combination will not be a problem.
Antibiotics such as the quinolones are not licensed for use in children; consequently, the range of antibiotics available for use in pediatric infections is more limited than that for adults. Ampicillin/sulbactam is likely to become increasingly important for the empiric management of pediatric infections as long as no emergence of resistance is reported.
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